APP and Alzheimer disease: In an IL-1β-induced AD animal model, EPA treatment (25 and 30 mg/kg) reduced the biomarkers of microglial CD11b and astrocyte glial fibrillary acidic protein (GFAP) expression, decreased the expression of APP and TNF-α, and upregulated the BDNF and the expression of its receptor tyrosine receptor kinase B (TrKB) in the hippocampus.